<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> or <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> due to synergistic effects on the inhibition of DNA repair </plain></SENT>
<SENT sid="1" pm="."><plain>Among 137 patients treated with fludarabine combination regimens, ten patients developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/sAML, including one who had received no other therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Six patients had abnormalities of chromosomes 5 and/or 7 </plain></SENT>
<SENT sid="3" pm="."><plain>The crude rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28) </plain></SENT>
<SENT sid="4" pm="."><plain>The rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy </plain></SENT>
</text></document>